Opinion statement
-
Cerebral venous thrombosis is a rare disorder with highly variable and nonspecific clinical presentations. For these reasons, specific treatment should be given only when the diagnosis has been firmly established. Etiologic diagnosis should begin in the emergency department to identify underlying conditions that require specific treatment.
-
The mainstay of treatment is anticoagulation with heparin, even in the case of cerebral hemorrhage, followed as soon as possible by oral anticoagulant administration. The optimal duration of oral anticoagulation has not been established. By analogy with systemic venous thrombosis, it should be prolonged 3 to 6 months. When a high risk of recurrence is present, treatment should be continued until the risk disappears.
-
In contrast to arterial stroke, complete recovery of prolonged or severe neurologic deficit is possible, justifying initiation of anticoagulation even when the clinical situation seems desperate. For the same reason, aggressive treatment of intracranial hypertension and seizures or status epilepticus is warranted.
-
Screening for extraneurologic venous thrombosis should be done by means of clinical examination and, if necessary, specific imaging procedures.
-
Local thrombolysis is not yet of proven efficacy and safety. It can be used in patients with clinical worsening related to documented extension of the venous thrombosis despite anticoagulation and in the absence of cerebral hematoma.
-
Surgical treatment is limited to external ventricular drainage and suboccipital craniotomy in the very rare cases of cerebellar vein thrombosis with edematous cerebellar infarct.
Similar content being viewed by others
References and Recommended Reading
Bousser MG, Chiras J, Bories J, Castaigne P: Cerebral venous thrombosis—a review of 38 cases. Stroke 1985, 16:199–213. This is a reference article describing the various clinical, neuroimaging, and outcomes patterns in CVT and the good tolerance of anticoagulant treatment.
Bousser MG: Cerebral Venous Thrombosis. Philadelphia: W.B. Saunders Co.; 1997. The only recent reference book on CVT, describing pathophysiology, clinical presentation, diagnosis, prognosis, and treatment of all known forms of CVT.
Crawford SC, Digre KB, Palmer CA, et al.: Thrombosis of the deep venous drainage of the brain in adults. Arch Neurol 1995, 52:1101–1108. A precise clinical and radiologic description of seven cases of a rare but sometimes devastating form of CVT, diagnosis of which can often be suspected on unenhanced CT scanning.
DiNubile MJ: Septic thrombosis of the cavernous sinuses. Arch Neurol 1988, 45:567–572.
Kuehnen J, Schwartz A, Neff W, et al.: Cranial nerve syndrome in thrombosis of the transverse/sigmoid sinuses. Brain 1998, 121:381–388.
Jacobs K, Moulin T, Bogousslavsky J, et al.: The stroke syndrome of cortical venous thrombosis. Neurology 1996, 47:376–382.
Lafitte F, Boukobza M, Guichard JP, et al.: Deep cerebral venous thrombosis: imaging in eight cases. Neuroradiology 1999, 41:410–418.
Ozsvath RR, Casey SO, Lustrin ES, et al.: Cerebral venography: comparison of CT and MR projection venography. Am J Roentgenol 1997, 169:1699–1707. A rigorous comparative study showing that CT venography is at least as efficient as magnetic resonance venography in the diagnosis of CVT; it is possibly superior in the differential diagnosis of hypoplastic sinus with low-flow phenomenon and dural sinus thrombosis.
Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999, 353:1167–1173. An excellent review of the multifactorial pathogenesis of venous thrombosis, with several references to CVT.
De Bruijn SFTM, Stam J, Koopman MMW, et al.: Casecontrol study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998, 316:589–592.
Martinelli I, Sacchi E, Landi G, et al.: High risk of cerebralvein thrombosis in carriers of a prothrombingene mutation and in users of oral contraceptives. N Engl J Med 1998, 338:1793–1797. A case-control study showing the high incidence of two congenital thrombophilia (factor V Leiden and prothrombin) mutations in idiopathic CVT and their interaction with oral contraceptive agents.
Zuber M, Toulon P, Marnet L, et al.: Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996, 27:1721–1723.
Ludemann P, Nabavi DG, Junker R, et al.: Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke 1998, 29:2507–2510.
Reuner KH, Ruf A, Grau A, et al.: Prothrombin gene G20210®A transition is a risk factor for cerebral venous thrombosis. Stroke 1998, 29:1765–1769.
Christopher R, Nagaraja D, Dixit NS, et al.: Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurol Scand 1999, 99:121–124.
Wilder-Smith E, Kothbauer-Margreiter I, Lämmle B, et al.: Dural puncture and activated protein C resistance: risk factors for cerebral venous thrombosis. J Neurol Neurosurg Psychiatry 1997, 63:351–356.
Brucker AB, Vollert-Rogenhofer H, Wagner M, et al.: Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis 1998, 8:331–337.
Einhäupl KM, Villringer A, Meister W, et al.: Heparin treatment in sinus venous thrombosis. Lancet 1991, 338:597–600. The first randomized controlled trial in CVT, showing a diminution in deaths and handicapping together with good tolerance of heparin in CVT complicated by cerebral hemorrhage.
Bergui M, Bradac GB, Danielle D: Brain lesions due to cerebral venous thrombosis do not correlate with sinus involvement. Neuroradiology 1999, 41:419–424. A multimodal radiologic study showing that parenchymatous lesions in CVT correlate with the involvement of cerebral veins, not the dural sinus.
Hirsh J, Dalen JE, Anderson DR, et al.: Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998, 114:445S-469S.
Einhäupl KM, Masuhr F: Cerebral venous and sinus thrombosis: an update. Eur J Neurol 1994, 1:109–126.
De Bruijn SFTM, Stam J: Randomized, placebo-controlled trial of anticoagulant treatment with lowmolecular-weight heparin for cerebral sinus thrombosis. Stroke 1999, 30:484–488. A randomized controlled trial of nadroparin versus placebo in CVT that was negative despite fewer deaths in the group receiving nadroparin.
Bousser MG: Cerebral venous thrombosis. Nothing, heparin, or local thrombolysis? Stroke 1999, 30:481–483. A critical editorial on the various therapeutic options in CVT with analysis of the literature.
Raschke RA, Reilly BM, Guidry JR, et al.: The weightbased heparin dosing nomogram compared with a “standard-care” nomogram. A randomized controlled trial. Ann Intern Med 1993, 119:874–881. Description of a weight-based nomogram and of a randomized controlled trial showing its efficiency and safety.
Pohl C, Klockgether T, Greinacher A, et al.: Neurological complications in heparin-induced thrombocytopenia. Lancet 1999, 353:1678–1679.
Schulman S, Rhedin AS, Lindmaker P, et al.: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995, 332:1661–1665.
Preter M, Tzourio C, Ameri A, et al.: Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996, 27:243–246.
Hyers TM, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolic disease. Chest 1998, 114:561S-578S.
Horowitz M, Purdy P, Unwin H, et al.: Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995, 38:58–67.
Gordon Smith A, Cornblath WT, Deveikis JP: Local thrombolytic therapy in deep cerebral venous thrombosis. Neurology 1997, 48:1613–1619.
Kasner SE, Gurian JH, Grotta JC: Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction. J Stroke Cerebrovasc Dis 1998, 7:421–425.
Philips MF, Bagley LJ, Sinson GP, et al.: Endovascular thrombolysis for symptomatic cerebral venous thrombosis. J Neurosurg 1999, 90:65–71.
Frey JL, Muro GJ, McDougall CG, et al.: Cerebral venous thrombosis. Combined intrathrombus rtPA and intravenous heparin. Stroke 1999, 30:489–494.
Corvol JC, Oppenheim C, Manaï R, et al.: Diffusionweighted magnetic resonance imaging in a case of cerebral venous thrombosis. Stroke 1998, 29:2649–2652.
Keller E, Flacke S, Urbach H, et al.: Diffusion- and perfusion-weighted magnetic resonance magnetic imaging in deep cerebral venous thrombosis. Stroke 1999, 30:1144–1146. A case report discussing the pathophysiology of the neurologic manifestations of CVT and its exploration with new magnetic resonance imaging techniques.
Hsu LC, Lirng JF, Fuh JL, et al.: Proton magnetic resonance spectroscopy in deep cerebral venous thrombosis. Clin Neurol Neurosurg 1998, 100:27–30.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niclot, P., Bousser, M.G. Cerebral venous thrombosis. Curr Treat Options Neurol 2, 343–352 (2000). https://doi.org/10.1007/s11940-000-0051-9
Issue Date:
DOI: https://doi.org/10.1007/s11940-000-0051-9